



Fasenra in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

IMMUNOLOGY · SEVERE EOSINOPHILIC ASTHMA, EGPA

The clinical situation

Fasenra (benralizumab) is a subcutaneous anti-IL-5R alpha monoclonal antibody FDA-approved for add-on maintenance therapy of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). Manufactured by AstraZeneca. Dosing is 30 mg SC every 4 weeks for the first three doses, then every 8 weeks thereafter. Pre-treatment workup confirms eosinophilic phenotype, reviews parasitic infection risk, and ensures vaccination currency per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your pulmonologist or allergist documents severe eosinophilic asthma or EGPA, eosinophil counts, exacerbation history, and Fasenra rationale.
- 2 Baseline screening.** Parasitic infection screen, vaccinations, and baseline eosinophil count documented per FDA labelling.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, and chain-of-custody plan; DHA or DoH approvals align where applicable.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; first dose administered with subsequent q8w maintenance per protocol.

Indicative economics

Reference US cash-pay range: USD 5,000–6,000 per dose (q8w maintenance) of Fasenra (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from AstraZeneca authorised distribution.

Documentation. Physician kit tailored to MoHAP / DHA / DoH review, with severe-asthma biologic class annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each dosing cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Fasenra × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/fasenra-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team